The sPD1/MS vaccine exhibited promising anti-tumor effects, increased levels of tumor-infiltrating CD8T cells by 6.5-fold (from 0.10 to 0.65%) in a mouse model of lung cancer. This evidence concerns the gene HOXD13 and lung carcinoma.